Management Change Announcement
Syngene International Limited announced a significant leadership change with Siddharth Mittal assuming the role of Managing Director and Chief Executive Officer effective July 1, 2026. He succeeds Peter Bains, who completed his tenure as Managing Director & CEO on June 30, 2026.
Background of New CEO
Siddharth Mittal brings close to three decades of business leadership experience to Syngene. He joins from Biocon Limited, where he most recently served as Managing Director and Chief Executive Officer. During his thirteen years at Biocon, Mittal held the position of Chief Financial Officer before being appointed Managing Director and CEO.
At Biocon, Mittal played a pivotal role in shaping the company's strategic direction for long-term growth, strengthening commercial operations, expanding global market presence, securing key regulatory approvals, and successfully commercializing Biocon's GLP-1 portfolio across major international markets. He also led strategic partnerships and commercial initiatives that strengthened Biocon's competitive position while driving operational excellence, customer-centricity, and sustainable business growth.
Executive Commentary
Kiran Mazumdar-Shaw, Executive Chairperson of Syngene International, commented: "I am delighted to welcome Siddharth as the Managing Director and CEO of Syngene. Having worked closely with Siddharth for many years, I have seen firsthand his ability to lead businesses through period of change, build strong teams and deliver transformation and sustainable growth."
Mazumdar-Shaw added: "Having built a strong reputation for scientific excellence, quality and customer trust, Syngene is now at an inflection point in its journey. As the industry evolves and customer expectations continue to rise, I am confident Siddharth's leadership, commercial acumen and execution focus will help Syngene unlock its full potential and create long-term value for our customers, employees and shareholders."
New CEO's Strategic Priorities
Siddharth Mittal stated: "I am honoured to take on the role of Managing Director and CEO of Syngene. Over the years, the company has built exceptional scientific capabilities, a talented team, and gained the trust of customers across the world. These enduring strengths give us a solid platform to drive the next phase of long-term growth."
Mittal outlined his immediate priorities: "My immediate priority is to sharpen our commercial edge, strengthen delivery excellence and bring greater focus and discipline to execution across the business. By combining our scientific strengths and talented workforce with an unwavering focus on customer fulfilment and cost competitiveness, I am confident that we can restore growth momentum and reinforce Syngene's standing as a global leader in CRDMO services, while creating long-term value for all our stakeholders."
Company Background
Syngene International Ltd. is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. The company employs over 8,300 employees including 5,700+ scientists, with over 3 million square feet of specialized discovery, development, and manufacturing facilities across India and the U.S. Syngene works with approximately 400 global customers including multinationals such as BMS, GSK, Zoetis, and Merck KGaA.